We are live on ! Find out more
PHXM

PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM

Delisted

PHXM was delisted on the 8th of March, 2024.

Back to rankings

5 hedge funds and large institutions have $10.4M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

6% less capital invested

Capital invested by funds: $11.1M → $10.4M (-$668K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$22.8K
2
SFM
Sphera Funds Management
Israel
-$7.07K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$4.48M – – –
NMC
2
NEA Management Company
Maryland
$4.47M – – –
SFM
3
Sphera Funds Management
Israel
$853K -$7.07K -96 -0.8%
DG
4
Delek Group
Israel
$489K – – –
Millennium Management
5
Millennium Management
New York
$140K -$22.8K -310 -14%

PHXM Hedge Fund Activity: Q2 2019 in Review

5 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2019, worth a combined $10.4M — down 6% from $11.1M a quarter earlier.

Fund positioning in PHXM was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Millennium Management, cutting an estimated $22.8K.

  • 5 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $10.4M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2019, down 6% quarter-over-quarter.
  • 0 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2019 and 0 closed out.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2019 was Millennium Management, an estimated $22.8K sold.

Based on aggregated 13F filings for Q2 2019.